



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY

Study of the Acute Hemodynamic Effects of Inhaled Milrinone versus Inhaled Nitroglycerin on Mechanically Ventilated Patients with Pulmonary Hypertension after Mitral Valve Replacement Surgeries.

A Thesis

Submitted for partial fulfillment of master degree in intensive care medicine

Presented by

Ahmed Sarhan Farag Saeed

M.B.B.CH- Faculty of Medicine, Ain Shams University.

Supervised by

PROF.DR. Sherif Sayed Ali Sultan

Professor of Anaesthesiology, Intensive Care & Pain management.

Faculty of Medicine, Ain Shams University.

DR. Wafaa El-Sayed Ismael Mostafa

Assistant Professor of Anaesthesiology, Intensive Care & Pain management.

Faculty of Medicine, Ain Shams University.

DR. Paula Micheal El-Komos Samaan

Lecturer of Anaesthesiology, Intensive care & Pain management.

Faculty of Medicine, Ain Shams University.

DR. Ahmed Kamel Abdel Ghany Hassan

Fellow of Cardiovascular medicine.

National Heart Institute.

(2021)

دراسة التأثيرات الحادة للدورة الدموية لمستنشق عقار الميلرينون مقابل
مستنشق عقار النيتروجليسرين علي المرضى الخاضعين للتهوية
الميكانيكية ذوي ضغط الدم الرئوي المرتفع بعد عمليات استبدال الصمام
الميتراي.

مقدمة من

أحمد سرحان فرج سعيد

بكالوريوس الطب والجراحة

جامعة عين شمس.

تحت إشراف

الأستاذ الدكتور/ شريف سيد علي سلطان

أستاذ بقسم التخدير والرعاية المركزة وعلاج الالام
جامعة عين شمس.

الدكتور/ وفاء السيد اسماعيل مصطفى

أستاذ مساعد بقسم التخدير والرعاية المركزة وعلاج الالام
جامعة عين شمس.

الدكتور/ بولا ميشيل القمص سمعان

مدرس التخدير والرعاية المركزة وعلاج الالام
جامعة عين شمس.

الدكتور/ أحمد كامل عبد الغني حسن

زميل أمراض القلب والأوعية الدموية
معهد القلب القومي.

(٢٠٢١)

Acknowledgement

First at all, all gratitude is due to Allah almighty for blessing this work, until it has reached its end, as a part of his generous help throughout my life. I can hardly find the words to express my gratitude to Professor Dr. Sherif Sayed Ali Sultan, Professor of Anaesthesiology ,Intensive Care and Pain management, Faculty of Medicine, Ain Shams University, for his close supervision, continuous help and encouragement throughout the whole work. It was a great honor to work under his guidance. Also, I want to thank Professor Dr. Wafaa El-Sayed Ismael Mostafa, Assistant Professor of Anaesthesiology, Intensive Care and Pain management, Faculty of Medicine, Ain Shams University, for her great help. She granted me a great deal of her precious time and effort guiding me throughout the preparation of this thesis. I'd like also to express my sincere appreciation and gratitude to Dr. Paula Micheal El-Komos Samaan, Lecturer of Anaesthesiology, Intensive care and Pain management, Faculty of Medicine, Ain Shams University, for his continuous support throughout the work and tremendous effort he has done in the meticulous revision of the whole work. I am extending my thanks to Dr. Ahmed Kamel Abdel Ghany Hassan, Fellow of Cardiovascular medicine, National Heart Institute ,for his support. I am extremely grateful to my parents for their love, prayers, caring and sacrifices for educating and preparing me for my future.

Contents

Acknowledgement	1
List of abbreviations	3
List of figures.....	7
List of tables	10
Introduction.....	12
Aim of work.....	16
Pathophysiology of pulmonary hypertension.....	18
Pathogenesis of pulmonary hypertension.....	30
Pharmacology of milrinone	41
Pharmacology of nitroglycerin.....	53
Patients and methods	68
Results.....	79
Discussion	102
Conclusion	113
English summary	114
References.....	121
Arabic summary	131

List of abbreviations

ALK-1	Anaplastic Lymphoma Kinase -1 gene
APTT	Activated Partial Thromboplastin Time
ATP	Adenosine Triphosphate
ATPase	Adenosine Triphosphatase
A-V node	Atrioventricular node
BMPR2	Bone Morphogenetic Protein Receptor type II
c-AMP	Cyclic Adenosine Monophosphate
CAV 1	Caveolin 1
c-GMP	Cyclic Guanosine Monophosphate
CI	Cardiac Index
CO	Cardiac Output
CPB	Cardiopulmonary Bypass
CTD	Connective Tissue Disease
CTEPH	Chronic Thromboembolic Pulmonary Hypertension
CVP	Central Venous Pressure
CW	Continuous Wave
DBP	Diastolic Blood Pressure
DPAP	Diastolic Pulmonary Artery Pressure
EF	Ejection Fraction
ENG	Endoglin
FiO ₂	Fraction of Inspired Oxygen

FS	Fractional Shortening
GMP	Guanosine monophosphate
GTP	Guanosine Triphosphate
HIF-1	Hypoxia-Inducible Factor -1
HIV	Human Immunodeficiency Virus
HPAH	Heritable Pulmonary Arterial Hypertension
HR	Heart Rate
IL-1 β	Interleukin 1 beta
IL2	Interleukin-2
IL-6	Interleukin-6
IL-8	Interleukin-8
IL-10	Interleukin-10
IL-12	Interleukin-12
iNO	Inhaled Nitric Oxide
IPAH	Idiopathic Pulmonary Artery Hypertension
IV	Intravascular
KCNK3	Potassium Channel subfamily K member 3 gene
LHD	Left Heart Disease
LVEF	Left Ventricle Ejection Fraction
MBP	Mean Arterial Blood Pressure
mPAP	Mean Pulmonary Artery Pressure
m-RNA	Messenger Ribonucleic Acid
mt-ALDH	Mitochondrial Aldehyde Dehydrogenase
NFAT	Nuclear Factor of Activated T-cells

NIH	National Institutes of Health
NO	Nitric Oxide
NS	Non-Significant
OR	Operating Room
PA banding	pulmonary artery banding
PaO ₂	Arterial Oxygen Partial Pressure
PaO ₂ /FiO ₂ ratio	Ratio of arterial oxygen partial pressure to fractional inspired oxygen
PAP	Pulmonary artery pressure
PASS11	Power Analysis and Sample Size
PAWP	Pulmonary Artery Wedge Pressure
PDE	Phosphodiesterase Enzyme
PDE5	Phosphodiesterase Enzyme 5
PDK	Pyruvate Dehydrogenase Kinase
PGI ₂	Prostaglandin I ₂
PH	Pulmonary hypertension
PHG registry	Primary Health Care Registry
PPHN	Persistent Pulmonary Hypertension of The Newborn
PR	Pulmonary Regurgitation
PVR	Pulmonary Vascular Resistance
RAP	Right atrial pressure
REVEAL registry	Registry to Evaluate Early and Long-Term PH Disease Management

RHC	Right Heart Catheterization
RV	Right Ventricle
RVH	Right Ventricle Hypertrophy
RVF	Right Ventricle Failure
SBP	Systolic Blood Pressure
SD	Standard Deviation
SERCA-2a	Sarco/Endoplasmic Reticulum Calcium ATPase (encoded by the ATP2A2 gene)
SMAD9	Mothers Against Decapentaplegic Homolog(9)
SPAP	Systolic Pulmonary Artery Pressure
SPSS	Statistical Package for Social Science
TNF α	Tumor Necrosis Factor alpha
TR	Tricuspid Regurgitation
TRPC	Transient Receptor Potential Channels
TTE	Transthoracic Echocardiography
US	United States
VCV	Volume-Controlled Ventilation
WHO	World Health Organization
WU	Wood Units

List of figures

Figure 1 .Pulmonary arteries of the muscular type displaying obstructive arteriopathy in lungs of patients with PH.	27
Figure 2 .Examples of adaptive and maladaptive RV remodeling in PH.....	29
Figure 3 .Schematic representation of imbalance of vasodilatory and vasoconstricting substances	31
Figure 4 .Multiple pathways converge to induce pulmonary vascular proliferation in PH.	32
Figure 5 .Mechanisms that contribute to RV failure in PH.	34
Figure 6 .Structure of milrinone.	41
Figure 7 . (A) Jet nebulizer. (B) Mesh nebulizer.	49
Figure 8 .Jet nebulizer device	51
Figure 9 .Structure of nitroglycerin.	53
Figure 10 .Nitric oxide (NO) signaling pathways in the regulation of pulmonary vascular tone.	58
Figure 11 .Direct connection of an inhaler device within the ventilator circuit.....	71
Figure 12 .TR Vmax method for measuring SPAP.....	73
Figure 13 .Pulmonary regurgitation method for measuring mean and diastolic pulmonary artery pressure.	74
Figure 14 .Heart rate (HR) of the two groups before delivery of the drug (T1), after delivery of the drug (T2) and before extubation(T3).	86
Figure 15 .Systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean blood pressure (MBP) of the two study groups before delivery of the drug (T1), after delivery of the drug (T2) and before extubation(T3).	86
Figure 16 .Systolic pulmonary pressure (SPAP), diastolic pulmonary pressure (DPAP) and mean pulmonary pressure (mPAP) of the two study groups before delivery of the drug (T1), after delivery of the drug (T2) and before extubation (T3)..	87

Figure 17. Central venous pressure of the two study groups before delivery of the drug (T1), after delivery of the drug (T2) and before extubation (T3).	87
Figure 18. Left ventricle ejection fraction (LVEF) and fractional shortening (FS) of the two study groups before delivery of the drug (T1), after delivery of the drug (T2) and before extubation (T3).88	
Figure 19. PaO ₂ /FiO ₂ ratio of the two study groups before delivery of the drug (T1), after delivery of the drug (T2) and before extubation (T3).	88
Figure 20. Heart rate (HR) of milrinone group before delivery of the drug (T1), after delivery of the drug (T2) and before extubation (T3).....	92
Figure 21. Systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean blood pressure (MBP) of milrinone group before delivery of the drug (T1), after delivery of the drug (T2) and before extubation (T3)..	92
Figure 22. Systolic pulmonary pressure (SPAP), diastolic pulmonary pressure (DPAP) and mean pulmonary pressure (mPAP) of milrinone group before delivery of the drug (T1), after delivery of the drug (T2) and before extubation(T3).	93
Figure 23. Central venous pressure (CVP) of milrinone group before delivery of the drug (T1), after delivery of the drug (T2) and before extubation (T3)	93
Figure 24. Left ventricle ejection fraction (LVEF) and fractional shortening (FS) of milrinone group before delivery of the drug (T1), after delivery of the drug (T2) and before extubation (T3) 94	
Figure 25. PaO ₂ /FiO ₂ ratio of milrinone group before delivery of the drug (T1), after delivery of the drug (T2) and before extubation (T3).....	94
Figure 26. Heart rate of nitroglycerin group before delivery of the drug (T1), after delivery of the drug (T2) and before extubation (T3).....	98

Figure 27. Systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean blood pressure (MBP) of nitroglycerin group before delivery of the drug (T1), after delivery of the drug (T2) and before extubation (T3).	98
Figure 28. Systolic pulmonary pressure (SPAP), diastolic pulmonary pressure (DPAP) and mean pulmonary pressure (mPAP) of nitroglycerin group before delivery of the drug (T1), after delivery of the drug (T2) and before extubation (T3)..	99
Figure 29. Central venous pressure (CVP) of nitroglycerin group before delivery of the drug (T1), after delivery of the drug (T2) and before extubation (T3).	99
Figure 30. Left ventricle ejection fraction (LVEF) and fractional shortening (FS) of nitroglycerin group before delivery of the drug (T1), after delivery of the drug (T2) and before extubation (T3).	100
Figure 31. PaO ₂ /FiO ₂ ratio of nitroglycerin group before delivery of the drug (T1), after delivery of the drug (T2) and before extubation (T3)	100

List of tables

Table 1 .Interactions of nitroglycerin.	64
Table 2 . Demographic data of the two study groups.....	79
Table 3 . Data of the two study groups before drug delivery (T1).	81
Table 4 . Data of the two study groups after delivery of the drugs (T2).	83
Table 5 . Data of the two study groups just before extubation (T3).	85
Table 6 . Data of milrinone group before and after delivery of the drug.....	90
Table 7 . Data of milrinone group before delivery of the drug and before extubation.....	91
Table 8 . Data of nitroglycerin group before and after delivery of the drug.....	96
Table 9 . Data of nitroglycerin group before delivery of the drug and before extubation.....	97